Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bortezomib in Multiple Myeloma: CTRI/2025/01/079150 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/01/079150 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Irafamdastat in Muscle Spasticity: NCT06782490 Clinical Landscape Report 2026
16 October 2026
NCT06782490 clinical landscape for Muscle Spasticity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab in Dermatitis, Atopic: CTRI/2025/01/079089 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/01/079089 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RD-IIT-001 in Relapsing acute myeloid leukemia: NCT06786299 Clinical Landscape Report 2026
16 October 2026
NCT06786299 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Annamycin liposomal(Moleculin Biotech) in Acute Myeloid Leukemia: NCT06788756 Clinical Landscape Report 2026
16 October 2026
NCT06788756 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ATTO-1310 in Pruritus: NCT06787586 Clinical Landscape Report 2026
16 October 2026
NCT06787586 clinical landscape for Pruritus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HEMO-CAR-T cell therapy (Hemogenyx) in Relapsing acute myeloid leukemia: NCT06786533 Clinical Landscape Report 2026
16 October 2026
NCT06786533 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Lunsekimig in Dermatitis, Atopic: NCT06790121 Clinical Landscape Report 2026
16 October 2026
NCT06790121 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-74856665 in B-Cell Leukemia: NCT06788509 Clinical Landscape Report 2026
16 October 2026
NCT06788509 clinical landscape for B-Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Thalidomide in Extramedullary Plasmacytoma: NCT06793475 Clinical Landscape Report 2026
16 October 2026
NCT06793475 clinical landscape for Extramedullary Plasmacytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ESO-T01(EsoBiotec) in Multiple Myeloma: NCT06791681 Clinical Landscape Report 2026
16 October 2026
NCT06791681 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-231 in Neuromyelitis Optica: NCT06797024 Clinical Landscape Report 2026
16 October 2026
NCT06797024 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.